Madrigal Pharmaceuticals, Inc. (MDGL) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Madrigal Pharmaceuticals (MDGL) Q2 2026: ResDifera Patient Base Doubles, Underpinning $1.3B Trailing Sales Run-Rate
July 30, 2026
-
Madrigal Pharmaceuticals (MDGL) Q1 2026: ResDifera Patient Base Up 2.5x, Pipeline Expansion Accelerates MASH Leadership
May 06, 2026
-
Madrigal Pharmaceuticals (MDGL) Q4 2025: U.S. MASH Diagnosed Population Expands 50%, Extending Market Runway
February 23, 2026
-
Madrigal Pharmaceuticals (MDGL) Q3 2025: ResDifera Patient Base Jumps 28%, Secures Path to $1B+ Specialty Franchise
November 04, 2025
-
Madrigal Pharmaceuticals (MDGL) Q2 2025: ResDifera Run Rate Tops $800M as Patent Extension Secures Decade-Long Growth Runway
August 05, 2025
-
Madrigal Pharmaceuticals (MDGL) Q1 2025: 17,000+ Patients on ResDifera Signals Durable Specialty Launch Trajectory
July 04, 2025